Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Zura Bio LimitedNASDAQ: ZURA
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$225.59M, compared with -$170.57M a year earlier.
Context
- Net debt amounted to 98.7% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
- Net debt increased in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -32.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (109.41M) USD
- Year-over-year change
- +38.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (109.41M) | +38.0% |
| FY2024 | 2024-12-31 | (176.5M) | -76.8% |
| FY2023 | 2023-12-31 | (99.81M) | -1712.6% |
| FY2022 | 2022-12-31 | 6.19M | +948.7% |
| FY2021 | 2022-03-31 | (729.22K) | — |
Net Debt vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 net debt of -$225.59M is the lowest of the 11 companies compared; the peer median is -$32.61M.
- Its year-over-year change of -32.3% is the 7th highest of 11, against a peer median of -5.1%.
- Net debt amounts to 98.7% of total assets for ZURA, versus a peer median of 27.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.68B | +11687.6% | — | 1.7% | |
| Mar 2026 | $151.69M | -2.7% | — | 48.2% | |
| Mar 2026 | $14.25M | +465.6% | — | 8.0% | |
| Mar 2026 | $11.02M | +55.6% | — | 17.1% | |
| Mar 2026 | -$28.63M | -40.4% | — | 12.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | -$36.59M | +43.4% | — | 34.0% |
| Mar 2026 | -$46.92M | -79.3% | — | 21.1% | |
| Mar 2026 | -$62.1M | -140.9% | — | 63.0% | |
| Mar 2026 | -$70.77M | -73.2% | — | 52.4% | |
| Mar 2026 | -$187.39M | -7.5% | — | 76.4% | |
ZURAZura Bio Limited | Mar 2026 | -$225.59M | -32.3% | — | 98.7% |
| Peer median (excluding ZURA) | -$32.61M | -5.1% | — | 27.5% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.